Mounjaro

(Tirzepatide)

Mounjaro

Drug updated on 11/15/2023

Dosage FormInjection (subcutaneous; 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg per 0.5 mL in single-dose pen)
Drug ClassAgonists for glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors
Ongoing and Completed StudiesClinicalTrials.gov

Indication

  • Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Product Monograph / Prescribing Information

Document TitleYearSource
Mounjaro (tirzepatide) Prescribing Information.2022Lilly USA, LLC, Indianapolis, IN

Systematic Reviews / Meta-Analyses

Document TitleYearSource
Meta-analysis of head-to-head clinical trials comparing incretin-based glucose-lowering medications and basal insulin: an update including recently developed glucagon-like peptide-1 (GLP-1) receptor agonists and the glucose-dependent insulinotropic polypeptide/GLP-1 receptor co-agonist tirzepatide.2023Diabetes Obesity and Metabolism
A systematic review of the safety of tirzepatide-a new dual GLP1 and GIP agonist - is its safety profile acceptable?.2023Frontiers in Endocrinology
Weight loss efficiency and safety of tirzepatide: a systematic review.2023PLOS ONE
Efficacy and safety of tirzepatide for treatment of overweight or obesity. a systematic review and meta-analysis.2023International Journal of Obesity
Tirzepatide-Induced Gastrointestinal Manifestations: A Systematic Review and Meta-Analysis. 2023Cureus
Safety issues of tirzepatide (pancreatitis and gallbladder or biliary disease) in type 2 diabetes and obesity: a systematic review and meta-analysis. 2023Frontiers in Endocrinology
Efficacy and safety of tirzepatide, dual GLP-1/GIP receptor agonists, in the management of type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. 2023Diabetology & metabolic syndrome
Effect of tirzepatide on blood pressure and lipids: A meta-analysis of randomized controlled trials. 2023Diabetes, Obesity & Metabolism
Glucometabolic outcomes of GLP-1 receptor agonist-based therapies in patients with type 2 diabetes: a systematic review and network meta-analysis. 2023EClinical Medicine
Impact of a dual glucose-dependent insulinotropic peptide/glucagon-like peptide-1 receptor agonist tirzepatide on heart rate among patients with type 2 diabetes: A systematic review and pairwise and network meta-analysis. 2023Diabetes, Obesity & Metabolism
Tirzepatide for type 2 diabetes.2022ICER
Efficacy and safety of tirzepatide in patients with type 2 diabetes mellitus: a Bayesian network meta-analysis. 2022Frontiers in Pharmacology
Semaglutide for the treatment of type 2 diabetes mellitus: a systematic review and network meta-analysis of safety and efficacy outcomes.2022Diabetes & Metabolic Syndrome: Clinical Research & Reviews
Efficacy and safety of tirzepatide as novel treatment for type 2 diabetes: a systematic review and meta-analysis of randomized clinical trials. 2022Diabetes & Metabolic Syndrome: Clinical Research & Reviews
Optimal dose of tirzepatide for type 2 diabetes mellitus: A meta-analysis and trial sequential analysis.2022Frontiers in Cardiovascular Medicine
Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis.2022Diabetologia
Comparative effectiveness of glucagon-like peptide-1 receptor agonists for the management of obesity in adults without diabetes: a network meta-analysis of randomized clinical trials.2022Obesity Reviews
Efficacy and safety of tirzepatide in patients with type 2 diabetes: a systematic review and meta-analysis.2022Frontiers in Pharmacology
Efficacy and safety of tirzepatide in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized phase II/III trials.2021Pharmaceuticals